• linkedin
  • Increase Font
  • Sharebar

    Adalimumab effective but not a cure for uveitis

     

    However, the adalimumab group experienced more adverse events: 1052.5 per 100 person-years versus 971.7 per 100 person-years in the placebo group.

    The adalimumab group also had more serious adverse events: 28.8 per 100 person-years versus 13.6 in the placebo group. Of these, the researchers judged that 9.6 per 100 person-years in the adalimumab group and 6.8 per 100 person-years in the placebo group might have been related to the trial intervention.

    The most frequent were injection-site reaction and allergic reactions. Serious infections occurred at a similar rate in the two groups. But two cancers and one event each of active tuberculosis, latent tuberculosis, lupus or lupus-like reaction, and demyelinating disorder were reported in the adalimumab group.

    Related: 5 intriguing ARVO abstracts about uveitis

    Adverse events leading to discontinuation were also more common in the adalimumab group, including choroidal neovascularization, blurred vision, reduced visual acuity, fatigue, malaise, and suicidal ideation. The adalimumab group also had more respiratory tract infections.

    Mostly because of such adverse events, 18 patients in the adalimumab group and seven in the placebo group dropped out of the trial.

    The researchers also detected anti-adalimumab antibodies in three of the patients taking that medication. 

    The researchers speculated that patients might fare better taking adalimumab in clinical practice than in this trial because they could continue to take glucocorticoids as needed. But they noted that treatment failed by week 80 for most of the patients, suggesting that the treatment can’t be considered a cure.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow